Viking Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Viking Therapeutics, Inc. (VKTX) had Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number of 951.19 thousand shares as of 2021-03-31, per its 10-Q filed 2021-04-28.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber · last filed 2021-04-28
- 2021-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 951.19K shares.
- 2020-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 3.65M shares.
- 2020-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 3.78M shares.
- 2020-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 3.85M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number |
|---|---|
| 2021-03-31 | 951.19K shares 10-Q · filed 2021-04-28 |
| 2020-12-31 | 3.65M shares 10-K · filed 2021-02-17 |
| 2020-09-30 | 3.78M shares 10-Q · filed 2020-10-28 |
| 2020-06-30 | 3.85M shares 10-Q · filed 2020-07-29 |
| 2020-03-31 | 3.99M shares 10-Q · filed 2020-04-30 |
| 2019-12-31 | 4.00M shares 10-K · filed 2020-02-26 |
| 2018-12-31 | 4.52M shares 10-K · filed 2019-03-13 |
| 2018-03-31 | 6.69M shares 10-Q · filed 2018-05-09 |
| 2017-12-31 | 8.17M shares 10-K · filed 2018-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |